Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Novozymes, University of Texas, and More


Title: Methods for Eliminating or Reducing the Expression of a Gene in a Filamentous Fungal Strain

Patent Number: 8,716,023

Filed: Dec. 9, 2004

Lead Inventor: Howard Brody, Novozymes

Title: microRNA Compositions and Methods for the Treatment of Myelogenous Leukemia

Patent Number: 8,716,255

Filed: Aug. 11, 2008

Lead Inventor: Florian Kuchenbauer, British Columbia Cancer Agency

Title: Compositions and Methods for Silencing Ebola Virus Gene Expression

Patent Number: 8,716,464

Filed: July 20, 2010

Lead Inventor: Thomas Geisbert, University of Texas Medical Branch (Tekmira Pharmaceuticals)

Title: Kit for Making Induced Pluripotent Stem Cells using Modified RNAs

Patent Number: 8,716,465

Filed: Aug. 21, 2012

Lead Inventor: Derrick Rossi, Children's Medical Center

Title: microRNAs for Identification of Exposure to Lower Aliphatic Saturated Aldehydes and the Method of Identification using Thereof

Patent Number: 8,716,192

Filed: Nov. 29, 2012

Lead Inventor: Jae Chun Ryu, Korea Institute of Science and Technology

Title: Regulation of Metabolism by miR-378

Patent Number: 8,716,258

Filed: June 6, 2011

Lead Inventor: Eric Olson, University of Texas

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.